F Helling
Overview
Explore the profile of F Helling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goetz S, Helling F, Emrich D, Weyh T, Herzog H
Annu Int Conf IEEE Eng Med Biol Soc
. 2010 Nov;
2010:4862-5.
PMID: 21096907
Neuromuscular stimulation has become a central technique for research and clinical efforts in rehabilitation, but available devices still do not show the needed performance in strength and selectivity for this...
2.
Livingston P, Zhang S, Adluri S, Yao T, Graeber L, Ragupathi G, et al.
Cancer Immunol Immunother
. 1997 Jan;
43(6):324-30.
PMID: 9067403
Natural IgM antibodies against the melanoma cell-surface ganglioside GM2, and IgM antibodies induced by vaccination with GM2 adherent to bacillus Calmette-Guerin, have been correlated with increased disease-free and overall survival...
3.
Zhang S, Graeber L, Helling F, Ragupathi G, Adluri S, LLOYD K, et al.
Cancer Res
. 1996 Jul;
56(14):3315-9.
PMID: 8764127
Human mucin MUC1 is abundantly expressed in some cancers of epithelia] origin and is largely restricted to the apical surface of secretory cells in normal tissues. It is, therefore, a...
4.
Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz S, LLOYD K, et al.
Cancer Immunol Immunother
. 1995 Sep;
41(3):185-92.
PMID: 7553688
Mucins of colorectal carcinomas overexpress the cancer-associated disaccharides Thomsen-Friedenreich antigen (TF) and sialyl-Tn antigen (sTn), making these antigens suitable for active specific immunotherapy. Patients at high risk for recurrent colon...
5.
Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al.
Cancer Res
. 1995 Jul;
55(13):2783-8.
PMID: 7796403
The cell surface gangliosides GM2, GD2, and GD3 are often overexpressed in malignant melanoma. We have shown previously that immunization of melanoma patients with GM2 and Bacillus Calmette-Guérin induced an...
6.
Kitamura K, Livingston P, Fortunato S, STOCKERT E, Helling F, Ritter G, et al.
Proc Natl Acad Sci U S A
. 1995 Mar;
92(7):2805-9.
PMID: 7708728
Gangliosides, such as GM2, GD2, GD3, and 9-O-acetyl GD3, are receiving attention as targets for antibody-based and vaccine-based therapies of melanoma. GM2 appears to be a particularly immunogenic ganglioside in...
7.
Zhang S, Helling F, LLOYD K, Livingston P
Cancer Immunol Immunother
. 1995 Feb;
40(2):88-94.
PMID: 7882387
Melanomas and other cancers of neuroectodermal origin express multiple cell-surface gangliosides in patterns that vary significantly even within the same tumor type. Monoclonal antibodies (mAb) against four of these gangliosides...
8.
Livingston P, Adluri S, Helling F, Yao T, Kensil C, Newman M, et al.
Vaccine
. 1994 Nov;
12(14):1275-80.
PMID: 7856291
Increasing doses of saponin fraction QS-21 were administered as immunological adjuvant in a Phase 1 trial with a constant dose of the melanoma ganglioside GM2 covalently attached to keyhole limpet...
9.
Livingston P, Wong G, Adluri S, Tao Y, Padavan M, Parente R, et al.
J Clin Oncol
. 1994 May;
12(5):1036-44.
PMID: 8164027
Purpose: To perform a double-blind randomized trial with American Joint Commission on Cancer (AJCC) stage III melanoma patients for the following reasons: (1) to confirm our previous finding that patients...
10.
Helling F, Livingston P
Mol Chem Neuropathol
. 1994 Feb;
21(2-3):299-309.
PMID: 8086040
Gangliosides are known to be suitable targets for immune attack against cancer but they are poorly immunogenic. Active immunization with ganglioside/BCG or liposome vaccines results in moderate titer IgM antibody...